A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
夏清 朱帧 赵煜韬
浙江省宁波市北仑区滨海新城医院整形科,宁波 315830
通信作者:夏清,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
DOI:10.3760/cma.j.issn.1671-0290.2023.03.019
张庆雪 张莹莹 高东程 赵硕 李靖若
郑州大学第一附属医院乳腺外科,郑州 450052
通信作者:李靖若,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
DOI:10.3760/cma.j.issn.1671-0290.2023.02.023
任荣鑫 赵红艺
北京医院整形外科 国家老年医学中心 中国医学科学院老年医 学 研 究 院,北 京
100730
通信作者:赵红艺,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
DOI:10.3760/cma.j.issn.1671-0290.2023.03.020
Treatment with high-intensity statins, such as atorvastatin 20 mg upwards, results in a 36% proportional increase in new type 2 diabetes diagnoses compared to placebo, with the majority of the new diabetes occurring in people already close to the diabetes glycaemic threshold, according to this meta-analysis of participant-level data from the Cholesterol Treatment Trialists’ Collaboration published in The Lancet Diabetes & Endocrinology. A smaller 10% proportional increase occurs with low- or moderate-intensity statins. Although previous meta-analyses of summary data from the statin trials have highlighted this increased risk, they could not fully quantify the size and timing of increases or determine who is at greatest risk. People with pre-existing diabetes treated with statins are also at risk of worsening glycaemia, particularly with high-intensity statins. However, the benefits of statins in reducing cardiovascular events in those at high risk far outweigh the impact of these increases in incident type 2 diabetes, so this study should not change prescribing habits. Nonetheless, it reminds us of the importance of counselling regarding increasing glycaemia risk and of encouraging lifestyle discussions around weight, eating patterns, sleep and physical activity, which can not only reduce the risk of type 2 diabetes but also improve the cardiovascular risk the statin is being used to treat.
Pam Brown
GP in Swansea
Citation: Brown P (2024) Diabetes Distilled: Statin heart benefits outweigh diabetes risks. Diabetes & Primary Care 26: [Early view publication]
Effective management of exudate is crucial for ensuring timely wound healing. Summarised in this product focus are 11 clinical studies (incorporating the experience of 179 patients), indicating that the ActivHeal® PHMB Foam dressing range (Advanced Medical Solutions Ltd.) is effective at treating infected wounds, managing wound exudate, debridement/wound cleansing, and enhancing the quality of life in patients with a various wound types, including venous leg ulcers (VLU), diabetic foot ulcers (DFU), pressure ulcers (PU), burns and postoperative surgical wounds. The use of the antimicrobial agent polyhexamethylene biguanide (PHMB) provides an effective defence against a broad spectrum of microorganisms, including antibiotic-resistant microorganisms, commonly associated with wound colonisation and infection. This evaluation does not aim to be a systematic or narrative review but rather a selection of the most pertinent publications summarising the clinical evidence supporting ActivHeal PHMB Foam range for the treatment of various chronic and acute wounds.
Rebecca Forder
Senior Clinical Research Manager, Advanced Medical Solutions, Winsford, UK
Alan A Rogers
Independent Wound Care Consultant, Flintshire, UK
Karen Ousey
Professor of Skin Integrity, Director for the Institute of Skin Integrity and Infection Prevention, Department of Nursing and Midwifery, University of Huddersfield, Huddersfield, UK
Mark G Rippon
Visiting Clinical Research Fellow, Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Queensgate, Huddersfield, UK
Key words
Declaration of interest
This publication was supported by Advanced Medical solutions.
Negative pressure wound therapy (NPWT) supports the healing process by removing fluid and drawing out the infection from a wound, promoting the growth of new tissue. The device works by providing and distributing negative pressure evenly across the wound bed, either through the application of an open cell foam or a gauze dressing. NPWT provides a warm, moist wound bed while removing wound fluid that contains factors that inhibit cell growth, enhances wound oxygenation and improves the flow of blood and nutrients to the wound. NPWT also creates mechanical forces that influence the wound macroscopically, inducing cell proliferation, cell migration to the wound and angiogenesis. For infected wounds, the device can be used to instil antibiotics. In this article, a 57-year-old Caucasian woman with respiratory failure developed sepsis secondary to an intra-abdominal infection with abscess. Vancomycin 1mg/mL wound instillation, instilled as 100mL every 3 hours with a dwell time of 10 minutes, was administered concomitantly with intravenous vancomycin in the successful management of this patient.
Alison Bunnell
Doctor of Pharmacy Candidate 2022, North Dakota State University, Fargo, ND, USA
Erin Beauclair
Breanna Jones
Doctor of Pharmacy, Pharmacy Department, Sanford Medical Center Fargo, Fargo, ND, USA
Emily Greenstein
Advanced Practice Registered Nurse and Certified Nurse Practitioner, Wound Care, Sanford Medical Center Fargo, Fargo, ND, USA
Justin M Jones
Andrea R Clarens
Doctor of Pharmacy Pharmacy Department, Sanford Bemidji Medical Center, Bemidji, MN, USA
Declaration Emily Greenstein reports she has been a consultant for Urgo medical, 3M and Coloplast. 3M manufactures V. A.C VeraFlo. None of these manufacture or distribute vancomycin instillation described in this manuscript.
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。